Journal of Inflammation Research (Sep 2022)
DPP4 as a Potential Candidate in Cardiovascular Disease
Abstract
Si-Yu Chen,1,* Xiang-Quan Kong,1,2,* Ke-Fan Zhang,3,* Shuai Luo,1 Feng Wang,1 Jun-Jie Zhang1,2 1Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, People’s Republic of China; 2Department of Cardiology, Nanjing Heart Centre, Nanjing, People’s Republic of China; 3Department of General Surgery, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jun-Jie Zhang, Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, No. 68 Changle Road, Nanjing, 210006, People’s Republic of China, Tel/Fax +86-25-52208048, Email [email protected]: The rising prevalence of cardiovascular disease has become a global health concern. The occurrence of cardiovascular disease is the result of long-term interaction of many risk factors, one of which is diabetes. As a novel anti-diabetic drug, DPP4 inhibitor has been proven to be cardiovascular safe in five recently completed cardiovascular outcome trials. Accumulating studies suggest that DPP4 inhibitor has potential benefits in a variety of cardiovascular diseases, including hypertension, calcified aortic valve disease, coronary atherosclerosis, and heart failure. On the one hand, in addition to improving blood glucose control, DPP4 inhibitor is involved in controlling cardiovascular risk factors. On the other hand, DPP4 inhibitor directly regulates the occurrence and progression of cardiovascular diseases through a variety of mechanisms. In this review, we summarize the recent advances of DPP4 in cardiovascular disease, aiming to discuss DPP4 inhibitor as a potential option for cardiovascular therapy.Keywords: DPP4, DDP4 inhibitor, GLP-1, inflammation, cardiovascular disease
